{
  "name" : "dacemirror.sci-hub.se_journal-article_faa0a36a1e43747946e1663f3153e291_amior2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "The role of Cox-2 and prostaglandin E2 receptor EP3 in pancreatic β-cell death",
    "authors" : [ "Livnat Amior", "Rohit Srivastava", "Rita Nano", "Federico Bertuzzi", "Danielle Melloul" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "KEY WORDS: islet • palmitate • apoptosis • cyclooxygenase-2 • diabetes mellitus\nType 2 diabetes (T2D) is a complex metabolic disorder characterized by b-cell failure in the setting of insulin resistance. In early stages,b-cells adapt to changes in insulin sensitivity by varying insulin secretion. However, in susceptible subjects, whenb-cells fail to compensate for insulin resistance, T2D ensues. As nutrient excess persists, hyperglycemia (glucotoxicity) and elevated free fatty acids (FFAs, lipotoxicity) contribute to b-cell failure and subsequent apoptosis. Because most individuals with T2D, whether obese or lean, show a decrease in b-cell mass (1, 2), there is a growing interest in understanding the mechanisms that control b-cell survival and death. Cumulative evidence indicates that exposure to elevated saturated FFAs can induce b-cell dysfunction and death through multiple mechanisms, including oxidative stress, ceramide formation, ER stress, and inflammation (3–5).\nSaturated fatty acids cause b-cell failure and contribute to diabetes development in genetically predisposed\nindividuals. Lipid infusion in individuals who are genetically predisposed to T2D induces hepatic insulin resistance and impairs b-cell function (6). Individuals with high fasting levels of plasma FFAs have an elevated risk of developing T2D (6, 7).\nIt has been suggested that systemic low-grade inflammation plays a role in T2D. In the islets of individuals with T2D, a higher number of infiltrated macrophages has been detected, along with increased levels of cytokines and chemokines (8–10). The activation of the cyclooxygenase-2 (COX-2)–prostanoid pathway has been implicated in the pathogenesis of inflammatory diseases (11). Previous reports have indicated that COX-2 expression was induced in human islets exposed to high glucose andwas elevated in islets of db/dbmice, a mousemodel of T2D (12, 13). Important for this study, transgenic mice overexpressing COX-2 and themicrosomal PGE synthase 1 (mPGES-1) genes in b-cells showed a significant reduction in b-cell mass and severe hyperglycemia (14).\nSelective COX-2 inhibitors were previously tested and showed improved glucose-stimulated insulin secretion (GSIS) in INS-1E cells (15, 16) and inmouse islets (17), as well as a slight increase in insulin secretion in vivo in mice following a glucose load (17). However, differing results regarding the role of the prostaglandin E2 (PGE2), the most prevalent COX-2 product, on insulin secretion were reported. Although a few studies showed that PGE2 inhibited GSIS in HIT cells (18–20), ABBREVIATIONS: CLX, celecoxib; COX-2, cyclooxygenase-2; EP3, prostaglandin E2 receptor subtype 3; FCS, fetal calf serum; FFA, free fatty acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSIS, glucose stimulated insulin secretion; INS, insulin; PGE2, prostaglandin E2; siRNA, small interfering RNA; T2D, type 2 diabetes 1 Current affiliation: Niguarda Hospital, Milan, Italy. 2 Correspondence: Department of Endocrinology, Hadassah University Hospital, P.O. Box 12000, Jerusalem 91120, Israel. E-mail: daniellem@ ekmd.huji.ac.il doi: 10.1096/fj.201801823R\n0892-6638/19/0033-0001 © FASEB 1\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\nothers reported a lack of inhibitory effect on insulin secretion in rat (21, 22) and human islets (21, 23). Moreover, an antiapoptotic effect of PGE2 and its precursor arachidonic acid in MIN6 and BRIN-BD11 cells was suggested (24, 25). PGE2 acts in an autocrine or paracrine manner and modulates responses via its binding to a family of 4 GPCRs termed EP1 (or PTGER1), EP2 (or PTGER2), EP3 (or PTGER3), and EP4 (or PTGER4). The EP subtypes exhibit differences in signal transduction, tissue localization, and regulation of expression (26). Evidence suggesting regulatory roles for PGE2 via its binding to its receptors and their associationwith stimulatory (Gs) or inhibitory (Gi) classes of G proteins in the modulation of insulin secretion has been described (18, 27–29). The involvement of PGE2 and EP3 in b-cell survival and proliferation in mouse and human islets in the presence of cytokines (30) has been reported. However, the roleofPGE2andEP3 in lipotoxicity-induced apoptosis has never been addressed. Elevatedexpressionof theEP3receptor in islets isolatedfrom individuals with T2D has previously been reported (29, 30); in the present study we support these findings and bring evidenceof elevatedexpressionof theEP3 receptor inb-cells exposed to palmitate or PGE2. Moreover, down-regulation of the pathway using pharmacological tools (inhibitor or antagonist) and the RNA interference approach to either COX-2 or EP3 decreased the levels of palmitate-induced apoptosis. Altogether, our data suggest that the COX-2PGE2-EP3 pathway contributes palmitate-induced apoptosis in b cells."
    }, {
      "heading" : "MATERIALS AND METHODS",
      "text" : ""
    }, {
      "heading" : "Reagents",
      "text" : "The COX-2 inhibitor celecoxib (CLX) was generously provided fromDr. Berta Brodsky (31), HebrewUniversity, Israel. Prostaglandin E2 - PGE2 was from Cayman Chemicals, Ann Arbor, MI, USA. Sodium palmitate (MilliporeSigma, Burlington, MA, USA) was dissolved in 95% ethanol at 60°C and added to the preheated medium. EP3 antagonist L798,106 (Tocris Bioscience, Bristol, United Kingdom)was dissolved in DMSO."
    }, {
      "heading" : "Islet and cell culture",
      "text" : "The pancreatic b-cell line MIN6 (32) was cultured in DMEM (Biologic Industries, Beit Haemek, Israel) supplemented with 11 mM glucose, 2 mM glutamine, 15% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, and 61 mM b-mercaptoethanol. Mouse islets were isolated from C57BL/6JOlaHsd female 12- to 16-wk-oldmice. The experiments designwas approved by the HebrewUniversity Research Ethics Committee.\nHuman islets were obtained from the European Consortium for Islet Transplantation (ECIT) at the San Raffaele Hospital and from the Niguarda Hospital, (Milan, Italy) (Table 1) and cultured in CMRL-1066 medium (Biologic Industries) supplementedwith 10% FCS, 5.5mMglucose, 2mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 150 mg/ml gentamycin. Palmitate was added to 1% FCS and 0.5% defatted bovine serum albumin (Roche, Basel, Switzerland).\nTransient transfection of the COX-2 gene\nMIN6cells (13106) grown in6-well disheswere transfectedwith indicated concentrations of mouse COX-2-cDNA expression vector in a pcDNA3 plasmid or with pcDNA3 empty vector, using the Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. RNA was extracted from the cells 48 h after transfection, and the relative mRNA expression levels of b-cell specific genes were measured by real-time PCR and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels."
    }, {
      "heading" : "Real-time PCR",
      "text" : "Total RNA from human islets isolated from 8 and 6 diabetic individuals or from MIN6 cells was extracted using TRIzol (Thermo Fisher Scientific). One to 2 micrograms of RNA was converted to cDNA using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s instructions. Ten to twenty nanograms of cDNAwas used for each real-time PCR reaction. Real-time reaction was performed using Platinum SYBR Green qPCR SuperMix-UDG with ROX reference dye (Thermo Fisher Scientific) andwas runusingABI Prism 7900 Sequence Detection System (Thermo Fisher Scientific). All the primers were optimized by standard curve, and their efficiency slope was between 23 and 23.6 (Table 2). RNA values were normalized to GAPDH or hypoxanthine phosphoribosyltransferase mRNA levels, and the relative mRNA levels were calculated relative to control samples. Densitometric analysis of data was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA)."
    }, {
      "heading" : "Western blotting",
      "text" : "Cells were lysed in Laemmli protein sample buffer, separated on SDS-polyacrylamide gel, and transferred to 0.2 mm nitrocellulose membranes (GE Healthcare, Waukesha, WI, USA) or Immobilon-P PVDF Membrane (0.45 mM) (Merck, Darmstadt, Germany). After blocking in 5% dried skimmed milk, the membranes were first incubated with the appropriate antibodies againstCOX-2 (CaymanChemicals); cleaved caspase-3 (Asp175) (Cell Signaling Technology, Danvers, MA, USA); and a-tubulin\n2 Vol. 33 April 2019 AMIOR ET AL.The FASEB Journal x www.fasebj.org\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\n(MilliporeSigma) and then with horseradish peroxidase conjugated anti-rabbit or anti-mouse IgG, followedbyanalysiswith an ECL detection kit (Biologics Industries Group, Beit Haemek, Israel).\nDetermination of glucose-stimulated insulin secretion and content\nAcute insulin release in response to glucose stimulation and insulin content was measured in human islets as previously described (33)."
    }, {
      "heading" : "Electroporation of small interfering RNA",
      "text" : "MIN6 cells were suspended in 100 ml of Amaxa nucleofector solution and electroporated with 1 mM of COX-2-small interfering RNA (siRNA), EP3-siRNA, or universal negative control-siRNA (Thermo Fisher Scientific) using program G-16 in the Amaxa nucleoporator (Lonza, Walkersville, MD, USA). The cells were transferred into fresh prewarmed MIN6medium immediately after electroporation and incubated\nfor 24 h before treatment. The mouse COX-2-siRNA sequence that was used is as follows: 59-AGGATTTGACCAGTATAAGT-39 (Qiagen, Germantown, MD, USA). The EP3 On-TargetPlus SmartPool siRNA (Thermo Fisher Scientific) that was used contains 4 siRNA sequences."
    }, {
      "heading" : "Determination of prostaglandin E2 concentrations",
      "text" : "PGE2 was secreted in media by the islets incubated for 48 h with palmitate in the presence of normal (5.5 mM) and was measured using a prostaglandin E2 ELISA Kit (Cayman Chemicals) according to the manufacturer’s instructions."
    }, {
      "heading" : "Statistical analysis",
      "text" : "Statistical significance for differences among groups was determined by use of 1-way ANOVA and Student’s t test to compare treated with untreated samples. All statistics were calculated using GraphPad software (La Jolla, CA, USA). A value of P,0.05 was considered statistically significant.\nTABLE 2. Primer sequences\nSequence, 59–39\nGene Forward Reverse\nHuman GAPDH GAGATCCCTCCAAAATCAA TCACACCCATGACGAACAT COX-2 TGCATTCTTTGCCCAGCACT AAAGGCGCAGTTTACGCTGT EP1 ATGGTGGGCCAGCTTGTC CCACCAACACCAGCATTGG EP2 CTCCTGGCTATCATGACCATCA TTCCTTTCGGGAAGAGGTTTC EP3 GGTCTCCGCTCCTGATAATGAT CTTCTCCGTGTGTGTCTTGCA EP4 CCCTGGTGGTGCTCATCTG TACTGACTTCTCGCTCCAAACTTG Mouse GAPDH CGTGTTCCTACCCCCAATGT TGCTTCACCACCTTCTTGATGT HPRT GCCGAGGATTTGGAAAAAGTG TCCCATCTCCTTCATGACATCTC COX-2 ACATGGACTCACTCAGTTTGTTGAG GCTTGTACAGCAATTGGCACAT INS1 AACCCCCAGCCCTTAGTGA GGGTAGGAAGTGCACCAACAG INS2 ACCCACAAGTGGCACAACTG GATCTACAATGCCACGCTTCTG GLUT2 CTTGTGCTGCTGGATAAATTCG ACCTGGCCCAATCTCAAAGA PDX-1 AGCTCCCTTTCCCGTGGAT GGCAGTACGGGTCCTCTTGTT EP1 GAGCAGCACTGGCCCTCTT TTGGCAGCACCACAGATGTATT EP2 CCATCACCTTCGCCATATGC CTCGGAGGTCCCACTTTTCC EP3 GAAGTTCTGCCAGATGATGAACAA CCTTCCCTGGGAGAAGAAATTC EP4 CTCGTGGTGCGAGTGTTCAT AATCCTGATGGCCTGCAAAT\nGLUT2, glucose transporter 2; HPRT, hypoxanthine phosphoribosyltransferase; PDX, pancreatic duodenal homeobox 1.\nPROSTAGLANDIN E2 RECEPTOR EP3 IN PANCREATIC b-CELL DEATH 3\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article."
    }, {
      "heading" : "RESULTS",
      "text" : "COX-2 expression is elevated in islets from individuals with T2D and in control human islets exposed to palmitate\nThe COX-2 enzyme and its major product, PGE2, have been implicated in the pathogenesis of several inflammatory diseases, including islet dysfunction under diabetic conditions.COX-2 expressionwas up-regulated in human\nislets cultured in high glucose (12, 13) and db/db mouse islets (12, 13). Thus, we examined whether a correlation exists between the glucose-induced COX-2 increase observed in vitro in human islets cultured inhighglucose and T2D disease. To this end, we measured the expression levels of this gene in islets isolated (Table 1) from 6 individuals with T2D and from 8 nondiabetic subjects. Realtime RT-PCR results revealed that COX-2 expression was significantly higher in diabetic islets when comparedwith control islet preparations. The average fold increase of COX-2 mRNA levels in islets of patients with T2D was 3.66 6 0.48 compared with 1.08 6 0.107 in the control group (Fig. 1).\nBecause elevated serum levels of circulating FFAs have also been associatedwith T2D, and given that exposure to saturated FFAs such as palmitate can induce b-cell dysfunctionanddeath,we examinedwhether the latter affects COX-2 gene expression. Thus, human islets exposed to 0.5 mM palmitate for 6, 24, and 48 h showed a timedependent increase in COX-2 expression at both mRNA (Fig. 2A) andprotein (Fig. 2B) levels. PGE2productionwas measured in the medium of pancreatic human islets incubatedwithpalmitate for 48h innormal (5.5mM)orhigh (25 mM) glucose concentrations. Similar increase in PGE2 levels by palmitate was observed independently of the glucose concentration (Fig. 2C).\n4 Vol. 33 April 2019 AMIOR ET AL.The FASEB Journal x www.fasebj.org\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\nRole of COX-2 in palmitate and glucoseinduced dysfunction in human islets\nTo evaluate the contribution of COX-2 activity to the deleterious effects of high glucose and palmitate on b-cell functions, the COX-2-selective inhibitor CLX was used. Insulin secretion and content were examined in human islets exposed for 9 d to normal (5.5 mM) or to high (25mM)glucose concentrations in the presence or absence\nof 0.5mMpalmitate during the last 48hof incubationwith or without CLX. The inhibitor partially restored the acute glucose-stimulated insulin secretion GSIS (Fig. 3A) and insulin content (Fig. 3B) in islets exposed to palmitate but only under normal glucose conditions. Actually, in the presence of high glucose, CLX had little or no effect on acute GSIS and insulin content. This is in accordance with the lack of effect by CLX on insulin secretory capacity observed in human islets thatwere chronically exposed to high glucose concentrations only (data not shown).\nEffect of palmitate on COX-2 expression in"
    }, {
      "heading" : "MIN6 cells",
      "text" : "Because the islets of Langerhans are composed of several cell types,MIN6b-cellswereused to ascribe thepalmitateinduced expression of COX-2 observed in islets to the b-cell population. Similarly, MIN6 cells exposed to palmitate for 6, 12, 24, and 48 h revealed a gradual up-regulation of COX-2 in these cells, both at the mRNA (Fig. 4A) and protein (Fig. 4B) levels.\nCOX-2 overexpression inhibits insulin 1, insulin 2, glucose transporter 2, and pancreatic duodenal homeobox 1 gene expression in MIN6 cells\nTo assess the effect of COX-2 on b-cell specific gene expression,MIN6 cellswere transfectedwith 0.1, 1, and 4mg of an expression plasmid containing the mouse COX-2 cDNA sequence. MIN6 cells overexpressing COX-2, in comparison with those transfected with the plasmid pcDNA3 empty vector, at similar molar concentrations, exhibited a dose-dependent reduced expression of insulin 1 (INS1), insulin 2 (INS2), glucose transporter 2, and pancreatic duodenal homeobox 1 (Fig. 5).\nRole of COX-2 in palmitate-induced apoptosis\nIncreased b-cell death following exposure to palmitate is well documented (3, 4), as supported by the results presented in Fig. 6 showing that human islets exposed to\nPROSTAGLANDIN E2 RECEPTOR EP3 IN PANCREATIC b-CELL DEATH 5\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\npalmitate significantly increased the levels of the cleaved caspase-3 apoptoticmarker (Fig. 6A). Similarly,MIN6cells treated with either increasing concentrations of palmitate (0.3, 0.4, and 0.5 mM) for 24 h (Fig. 6B) or with 0.3 mM palmitate for 24 and 48 h (Fig. 6C) showed a gradual increase in apoptosis, in a dose- and time-dependent manner, as also assessed by the intensity of the cleaved caspase-3 fragment.\nTo further investigate the role of COX-2 expression in palmitate-induced apoptosis in b-cells, RNA interference was used to repress its expression levels. MIN6 cells were electroporated with COX-2 siRNA or control siRNA before palmitate treatment for 24 h, reducing themRNAand protein levels by 76 and 78%, respectively (Fig. 7A, B). Knockdown of COX-2 attenuated the palmitate-induced apoptosis ofMIN6cells, as demonstratedbya reductionof about 50% in caspase-3 activation using Western blot analysis (Fig. 7C).We then tested the contribution ofCOX2 enzymatic activity in palmitate-induced b-cell apoptosis by using the specific COX-2 inhibitor. Indeed, the addition of 10 mM CLX in palmitate-treated MIN6 for 24 h also reduced the intensity of cleaved caspase-3 fragment by 50% (Fig. 7D), confirming the role for COX-2 enzymatic activity in the apoptotic process.\nTaken together, the results reveal the role of COX-2 as 1 of the mediators of palmitate-induced apoptosis.\nDifferential expression of PGE2 receptors (EP1–4) in MIN6 cells, mouse islets, and human islets from nondiabetic individuals or individuals with T2D\nExposure of human islets to palmitate in the presence of normal or high glucose concentrations led to increased PGE2 secretion levels (Fig. 2C). The PGE2 response in cells depends on the expression pattern of the 4 receptors (EP1–4), which differ in the signal transduction they activate. To investigate the expression levels of these receptors, mRNA levels of EP1–4 were measured by real-time PCR in human and mouse islets, as well as in the mouse MIN6 b-cell line. The analysis revealed that although in human islets themost prevalent subtype of PGE2 receptor is EP3, in mouse islets and inMIN6 it is EP4 (Fig. 8A). The differential expression of each subtype is presented relative to the predominantly expressed one in each cell type.\nTo further investigate the relevance of the EP receptors in diabetes, RNA extracted from islets isolated from the 6 T2D and the 8 nondiabetic donors (Table 1) was analyzed forEP expression. In fact,EP3 expressionwas significantly higher in T2D islets (3.836 0.38-fold) comparedwith islets ofhealthydonors (1.0460.11-fold)normalized toGAPDH mRNA(Fig. 8B,C). In contrast the expression levels ofEP1, EP2, and EP4 receptors did not show significant differences between the 2 groups (Fig. 8B).\nRole of EP3 in palmitate- and PGE2-induced apoptosis in MIN6 cells\nTo assess whether a correlation exists between palmitateinduced COX-2 expression and EP3, MIN6 were exposed to palmitate (0.3 mM) or to PGE2 (100 mM) for 24 h. The results presented in Fig. 9A, C show a significant increase in EP3 mRNA expression levels in both treatments. To determine further the role this subtype receptor can play in apoptosis, MIN6 cells were electroporated with either EP3-specific or control siRNA before palmitate treatment for 24 h (Fig. 9A, B) or to PGE2 (Fig. 9C, D) for an additional 24 h. EP3 siRNA significantly reduced the\n6 Vol. 33 April 2019 AMIOR ET AL.The FASEB Journal x www.fasebj.org\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\nbasal and palmitate-induced EP3 mRNA levels by 47 and 70%, respectively (Fig. 9A), as well as that of basal (43%) and PGE2-induced (80%) expression (Fig. 9C). Concomitant with reduced EP3 expression, a significant decrease in apoptosis was observed in both palmitateand PGE2-treated cells by 55 and 57%, respectively, as measured by the cleaved-caspase 3 apoptotic marker (Fig. 9B, D).\nThe EP3 antagonist L-798,106 reduces palmitate-induced apoptosis in human islets and in MIN6 cells\nTo further confirm the role of EP3 in palmitate-induced apoptosis, the EP3 antagonist L-798,106 was added to MIN6 cells (10 or 20 mM) and to human islets (40 mM) for 1 h before the addition of 0.5 mM palmitate for an additional 48 h. A significant decrease in apoptosis was observed, as alsodeterminedby the reduced levels of cleaved caspase-3 inbothMIN6cells (Fig. 10A) and inhuman islets (Fig. 10B).\nTaken together by use of siRNA or the receptor antagonist, the results validate EP3 as one of the mediators of palmitate-induced b-cell apoptosis."
    }, {
      "heading" : "DISCUSSION",
      "text" : "Thepresent study is a follow-up study to aprevious report in which human islets chronically exposed to high glucose showed a reduced expression of the insulin and pancreatic duodenal homeobox 1 genes (33). This\ncorrelated with depleted insulin stores providing, in part, a mechanism involved in the so-called “glucotoxicity,” a relevant phenomenon for b-cell dysfunction in T2D. This line of research was pursued by using DNA microarray-based gene expression profiling to identify candidate genes with altered expression in human islets under similar conditions. COX-2 was one of the main glucose-up-regulated genes in human islets treated in vitro. Presently, we show that the expression of COX-2 is significantly elevated in islets isolated from individuals with T2D as compared with islets from nondiabetic subjects.\nHigher fasting FFA levels were prospectively found to be associated with a greater risk of subsequent impaired glucose tolerance and T2D (34). Fatty acids can favor the development of the disease by reducing insulin secretion and inducing apoptosis of pancreatic b cells (35, 36). Palmitate has been reported to trigger aberrant ER calcium release, which leads to impaired protein folding machinery and the accumulation of misfolded proteins. This ER stress may further aggravate oxidative stress by augmentingROSproduction. This vicious cycle of lipotoxicity results in b-cell failure and apoptosis (5).\nData reported herein demonstrate that exposure of pancreatic human islets and the MIN6 b-cell line to the fatty acid palmitate significantly increases COX-2 expression at both the mRNA and protein levels.\nThe implication of high COX-2 expression in b-cell death was tested by down-regulating its expression or its activity using small interfering specific COX-2 siRNA or the inhibitor CLX. Both approaches significantly inhibited palmitate-induced apoptosis, confirming the role of elevated COX-2 in b-cell demise.\nPROSTAGLANDIN E2 RECEPTOR EP3 IN PANCREATIC b-CELL DEATH 7\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\nThese observations are in linewith the results of a study that examined the in vivo effect of b-cell–specific expression of COX-2 in transgenic mice (14). In this model, the animals showed severe hyperglycemia as early as 6 wk of age, with a dramatic reduction in the relative number of b cells down to 54% in the heterozygotes and 14% in the homozygotes as well as a depletion of insulin stores and an impaired insulin secretion in response to a glucose load. Loss of b-cell mass has been suggested to contribute to the development of T2D (4, 37–39). Consistent with previous studies regarding the proapoptotic effect of FFA on human islets (40–42), we show that palmitate activated the apoptotic pathway, to the same extent in normal and in high glucose. This is in agreement with a report showing that high glucose increased apoptosis only in INS-1E but not in MIN6 or human islets, which were suggested to efficiently oxidize fatty acids at high glucose and therefore prevent the synergism suggested in glucolipotoxicity-induced apoptosis (43). It must be noted that although previous studies have reported glucose-induced apoptosis in human islets (44–48), under the current experimental conditions, cell death has never been detected in human islets chronically exposed to high glucose. Although the effect of selective COX-2 inhibitors and that of the predominant product PGE2 on insulin secretion was investigated decades ago, conflicting results were reported, ranging froman inhibitory toanonadverse effect on GSIS (14–18). The discrepancy could be due to the different experimental conditions used as well as to the originof theb cells tested suchasHITcells, or rat orhuman islets (21, 22, 49, 50). We have tested the effect of the COX2 inhibitor CLX on GSIS ex vivo in human islets exposed to palmitate in the presence of normal or high glucose. The inhibitor partially restored the acute GSIS and insulin content in islets exposed to palmitate but only under normal\n8 Vol. 33 April 2019 AMIOR ET AL.The FASEB Journal x www.fasebj.org\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\nglucose conditions. Actually, in the presence of high glucose, CLX had little or no effect on acute GSIS and insulin content. This is in accordance with the lack of effect by CLX on insulin secretory capacity observed in human islets that were chronically exposed to high glucose concentrations only (data not shown). We also tested the effect of COX-2 inhibition in vivo in a high-fat diet-induced insulin resistancemodel of diabetes. To this end, C56BL/6Jmicewere fed either on a regular chowor on a sustained high fat diet for 14 wk. The results obtained showed that although COX2 inhibitor had no significant effect on glucose disposal in animals fed on a normal diet, it worsened the glucose tolerance in mice fed with HFD, indicating that the general inhibition of PGE2 biosynthesis is detrimental in the setting of obesity in mice (data not shown).\nWe therefore focused our efforts on the downstream product PGE2 as a potential mediator of lipotoxicity. PGE2 binds to a family of receptors EP1–EP4. These receptors are distinct based on: 1) their binding affinity to the ligand, 2) the relative activity of different specific pharmacologic agonists or antagonists, and 3) the differences in signal transduction, tissue localization, and regulation of expression they exhibit under physiologic and pathologic conditions (26).This study presents the relative expression pattern of the EP subtypes in mouse and human islets as well as in the mouse b-cell line. In accordance with the findings in rats (51) and in humans (29), the most prevalent receptor in human islets is EP3. Consistent with previous observation, a selective elevated expression in T2D islets was observed only in EP3 and not in the additional PGE2 receptors EP1, EP2, and EP4 (29, 30). In the present study, we could not establish a correlation between the body mass index of the donors and the expression of EP3 in islets isolated from both diabetics and nondiabetics. Because EP3 is expressed in islet cells, it was important to validate the observed induced-EP3 expression in MIN6 b cells by palmitate and PGE2. These findings support the hypothesis that the damaging effects on b cells involve EP3, because reducing its expression levels using siRNA in MIN6 cells or blocking its activation using an antagonist in human islets as well as in MIN6 cells inhibited cell apoptosis. Tran et al. (27) suggested that the deleterious effects of IL-1b on b-cell functions involved the activation of NF-kB, which stimulates COX-2 expression. By inhibition of this enzyme using sodium salicylate, the activation of COX-2 and EP3 receptor expression was suppressed, thereby preventing IL-1b from inhibiting GSIS. EP3was also reported to be elevated in islets from diabetic BTBR mice and human T2D, and it was found that the EP3 antagonist improves GSIS (29). More recently, EP3 signalingwas reported to increase cytokineinduced b-cell death, whereas EP4 activation promotes b-cell survival and proliferation. It was proposed that multiple signaling pathways such as Akt and mTOR activities are inhibited by EP3 signaling reducing b-cell proliferation. Interestingly, increased expression of EP3 and more specifically that of the spliced variant EP3-g gene with age was observed, suggesting that enhanced\nPROSTAGLANDIN E2 RECEPTOR EP3 IN PANCREATIC b-CELL DEATH 9\nDownloaded from www.fasebj.org by Univ of New England Library (132.174.255.223) on January 10, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.\nPGE2 signaling via EP3 results in impaired b-cell proliferation in oldmice (30). Neuman et al. (52) presented a different approach of showing the involvement of EP3 in b-cell function. In this study, reduction of PGE2 production and EP3 expression due to dietary eicosapenaenoic acid (another COX-2 substrate) enrichment led to enhancement of BTBR diabetic mouse islets function and improved glucose tolerance and b-cell function in the NOD mouse model of type 1 diabetes. Eicosapenaenoic acid competes with AA on the COX-2 enzyme activity and shifts the prostaglandin production toward an increase in PGE3:PGE2 ratio limiting EP3 signaling in b-cells.\nIn summary, we present evidence that exposure of human islets and a b-cell line to palmitate induces apoptosis by stimulating the expression of the proinflammatory COX-2 gene and that of the downstream EP3 receptor. Decreasing their expression levels or activity or using a specific EP3 antagonist protects from palmitateinduced apoptosis. As mentioned before, several molecular mechanisms leading to palmitate-induced toxicity in b-cells have been demonstrated; we therefore propose an additional mechanism that involves COX-2 enzymatic activity and its metabolite PGE2 acting via the EP3 receptor.\nElevated COX-2 expression contributes to lipotoxicity in b-cells and strategies designed to inhibit the activity of\nthe EP3 receptor while retaining COX-2 functionmight be therapeutically useful."
    }, {
      "heading" : "ACKNOWLEDGMENTS",
      "text" : "The authors are grateful to Gerard Elberg and Ronit Sionov (both from The Hebrew University of Jerusalem–Hadassah Medical School, Jerusalem, Israel), for technical help and helpful discussions. This work was supported by a grant from the Israel Science Foundation (ISF 1370/15). The authors declare no conflicts of interest."
    }, {
      "heading" : "AUTHOR CONTRIBUTIONS",
      "text" : "L. Amior, R. Srivastava, and D. Melloul designed and performed research, and analyzed data; R. Nano and F. Bertuzzi contributed human islets preparations; and L. Amior and D. Melloul wrote the manuscript."
    } ],
    "references" : [ {
      "title" : "Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes",
      "author" : [ "A.E. Butler", "J. Janson", "S. Bonner-Weir", "R. Ritzel", "R.A. Rizza", "P.C. Butler" ],
      "venue" : "Diabetes",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2003
    }, {
      "title" : "Islet b cell mass in diabetes and how it relates to function, birth, and death",
      "author" : [ "G.C. Weir", "S. Bonner-Weir" ],
      "venue" : "Ann. N. Y. Acad. Sci. 1281,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2013
    }, {
      "title" : "Causes and cures for endoplasmic reticulum stress in lipotoxic b-cell dysfunction",
      "author" : [ "M. Cnop", "L. Ladrière", "M. Igoillo-Esteve", "R.F. Moura", "D.A. Cunha" ],
      "venue" : "Diabetes Obes. Metab",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2010
    }, {
      "title" : "Glucolipotoxicity of the pancreatic beta cell",
      "author" : [ "V. Poitout", "J. Amyot", "M. Semache", "B. Zarrouki", "D. Hagman", "G. Fontés" ],
      "venue" : "Biochim. Biophys. Acta",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2010
    }, {
      "title" : "Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes",
      "author" : [ "L.D. Ly", "S. Xu", "S.K. Choi", "C.M. Ha", "T. Thoudam", "S.K. Cha", "A. Wiederkehr", "C.B. Wollheim", "I.K. Lee", "K.S. Park" ],
      "venue" : "Exp. Mol. Med",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2017
    }, {
      "title" : "A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes",
      "author" : [ "S. Kashyap", "R. Belfort", "A. Gastaldelli", "T. Pratipanawatr", "R. Berria", "W. Pratipanawatr", "M. Bajaj", "L. Mandarino", "R. DeFronzo", "K. Cusi" ],
      "venue" : "Diabetes",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2003
    }, {
      "title" : "Atherosclerosis Risk in Communities Study",
      "author" : [ "J.S. Pankow", "B.B. Duncan", "M.I. Schmidt", "C.M. Ballantyne", "D.J. Couper", "R.C. Hoogeveen", "S.H. Golden" ],
      "venue" : "study.Diabetes Care",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2004
    }, {
      "title" : "Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes",
      "author" : [ "M.Y. Donath", "M. Böni-Schnetzler", "H. Ellingsgaard", "J.A. Ehses" ],
      "venue" : "Physiology (Bethesda)",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2009
    }, {
      "title" : "Increased number of islet-associated macrophages in type 2 diabetes",
      "author" : [ "J.A. Ehses", "A. Perren", "E. Eppler", "P. Ribaux", "J.A. Pospisilik", "R. Maor-Cahn", "X. Gueripel", "H. Ellingsgaard", "M.K. Schneider", "G. Biollaz", "A. Fontana", "M. Reinecke", "F. Homo-Delarche", "M.Y. Donath" ],
      "venue" : "Diabetes",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2007
    }, {
      "title" : "Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes",
      "author" : [ "M. Igoillo-Esteve", "L. Marselli", "D.A. Cunha", "L. Ladrière", "F. Ortis", "F.A. Grieco", "F. Dotta", "G.C. Weir", "P. Marchetti", "D.L. Eizirik", "M. Cnop" ],
      "venue" : "Diabetologia",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2010
    }, {
      "title" : "Cyclooxygenase in biology and disease",
      "author" : [ "R.N. Dubois", "S.B. Abramson", "L. Crofford", "R.A. Gupta", "L.S. Simon", "L.B. Van De Putte", "P.E. Lipsky" ],
      "venue" : "FASEB J",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 1998
    }, {
      "title" : "Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes",
      "author" : [ "S.J. Persaud", "C.J. Burns", "V.D. Belin", "P.M. Jones" ],
      "venue" : null,
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2004
    }, {
      "title" : "Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice",
      "author" : [ "N. Shanmugam", "I.T. Todorov", "I. Nair", "K. Omori", "M.A. Reddy", "R. Natarajan" ],
      "venue" : "Diabetologia",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2006
    }, {
      "title" : "Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets",
      "author" : [ "H. Oshima", "M.M. Taketo", "M. Oshima" ],
      "venue" : "J. Biol",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2006
    }, {
      "title" : "andSimell,O. (2002)Cellulardistributionand contribution of cyclooxygenase COX-2 to diabetogenesis in NOD mouse",
      "author" : [ "C. Luo", "M. Kallajoki", "R. Gross", "M. Mulari", "T. Teros", "L. Ylinen", "M. Mäkinen", "J. Laine" ],
      "venue" : "Cell Tissue Res",
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 2002
    }, {
      "title" : "Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism",
      "author" : [ "P. Shridas", "L. Zahoor", "K.J. Forrest", "J.D. Layne", "N.R. Webb" ],
      "venue" : "J. Biol",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2014
    }, {
      "title" : "Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice",
      "author" : [ "H. Fujita", "M. Kakei", "H. Fujishima", "T. Morii", "Y. Yamada", "Z. Qi", "M.D. Breyer" ],
      "venue" : "Biochem. Biophys. Res",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2007
    }, {
      "title" : "Receptor-mediated adenylate cyclase-coupledmechanism for PGE2 inhibition of insulin secretion",
      "author" : [ "R.P. Robertson", "P. Tsai", "S.A. Little", "H.J. Zhang", "T.F. andWalseth" ],
      "venue" : "HIT cells. Diabetes",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 1987
    }, {
      "title" : "Pertussis toxin-sensitive G protein mediation of PGE2 inhibition of cAMP metabolism and phasic glucose-induced insulin secretion",
      "author" : [ "E.R. Seaquist", "T.F. Walseth", "D.M. Nelson", "R.P. Robertson" ],
      "venue" : "HIT cells. Diabetes",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 1989
    }, {
      "title" : "Prostaglandin E2 regulates Foxo activity via the Akt pathway: implications for pancreatic islet beta cell dysfunction",
      "author" : [ "Z.X. Meng", "J.X. Sun", "J.J. Ling", "J.H. Lv", "D.Y. Zhu", "Q. Chen", "Y.J. Sun", "X. Han" ],
      "venue" : "Diabetologia",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2006
    }, {
      "title" : "Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets",
      "author" : [ "M.R. Heitmeier", "C.B. Kelly", "N.J. Ensor", "K.A. Gibson", "K.G. Mullis", "J.A. Corbett", "T.J. Maziasz" ],
      "venue" : "J. Biol",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2004
    }, {
      "title" : "Divergent effects of epinephrine and prostaglandin E2 on glucose-induced insulin secretion from perifused rat",
      "author" : [ "W.S. Zawalich", "K.C. Zawalich", "H. Yamazaki" ],
      "venue" : "islets. Metabolism",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2007
    }, {
      "title" : "Expression and function of cyclooxygenase and lipoxygenase enzymes in human islets of Langerhans",
      "author" : [ "S.J. Persaud", "D. Muller", "V.D. Belin", "A. Papadimitriou", "G.C. Huang", "S.A. Amiel", "P.M. Jones" ],
      "venue" : "Arch. Physiol. Biochem",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2007
    }, {
      "title" : "Anti-apoptotic effects of arachidonic acid and prostaglandin E2 in pancreatic beta-cells",
      "author" : [ "A. Papadimitriou", "A.J. King", "P.M. Jones", "S.J. Persaud" ],
      "venue" : "Cell. Physiol. Biochem",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2007
    }, {
      "title" : "Arachidonic acid actions on functional integrity and attenuation of the negative effects of palmitic acid in a clonal pancreatic b-cell line",
      "author" : [ "D.C. Keane", "H.K. Takahashi", "S. Dhayal", "N.G. Morgan", "R. Curi", "P. Newsholme" ],
      "venue" : "Clin. Sci. (Lond.)",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2011
    }, {
      "title" : "Prostaglandin E receptors",
      "author" : [ "Y. Sugimoto", "S. Narumiya" ],
      "venue" : "J. Biol",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2007
    }, {
      "title" : "Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1beta",
      "author" : [ "P.O. Tran", "C.E. Gleason", "V. Poitout", "R.P. Robertson" ],
      "venue" : "J. Biol",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 1999
    }, {
      "title" : "2005)Arole forG(z) inpancreatic isletbeta-cell biology",
      "author" : [ "M.E. Kimple", "A.B. Nixon", "P. Kelly", "C.L. Bailey", "K.H. Young", "T.A. Fields", "P.J. andCasey" ],
      "venue" : "J. Biol",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2005
    }, {
      "title" : "2013)Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion",
      "author" : [ "M.E. Kimple", "M.P. Keller", "M.R. Rabaglia", "R.L. Pasker", "J.C. Neuman", "N.A. Truchan", "H.K. Brar", "A.D. andAttie" ],
      "venue" : "Diabetes",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 1912
    }, {
      "title" : "Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human b-cell survival and proliferation.Mol",
      "author" : [ "B.A. Carboneau", "J.A. Allan", "S.E. Townsend", "M.E. Kimple", "R.M. Breyer", "M. Gannon" ],
      "venue" : null,
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2017
    }, {
      "title" : "2004)Reduced sulfurmustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treatedmice",
      "author" : [ "U. Wormser", "R. Langenbach", "S. Peddada", "A. Sintov", "B. Brodsky", "A. andNyska" ],
      "venue" : "Toxicol. Appl. Pharmacol",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2004
    }, {
      "title" : "Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter",
      "author" : [ "J. Miyazaki", "K. Araki", "E. Yamato", "H. Ikegami", "T. Asano", "Y. Shibasaki", "Y. Oka", "K. Yamamura" ],
      "venue" : "isoforms. Endocrinology",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 1990
    }, {
      "title" : "Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose",
      "author" : [ "S. Marshak", "G. Leibowitz", "F. Bertuzzi", "C. Socci", "N. Kaiser", "D.J. Gross", "E. Cerasi", "D. Melloul" ],
      "venue" : "Diabetes",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 1999
    }, {
      "title" : "Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes",
      "author" : [ "B. Salgin", "K.K. Ong", "A. Thankamony", "P. Emmett", "N.J. Wareham", "D.B. Dunger" ],
      "venue" : "J. Clin. Endocrinol. Metab",
      "citeRegEx" : "34",
      "shortCiteRegEx" : "34",
      "year" : 2012
    }, {
      "title" : "Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function",
      "author" : [ "K. Maedler", "J. Oberholzer", "P. Bucher", "G.A. Spinas", "M.Y. Donath" ],
      "venue" : "Diabetes",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2003
    }, {
      "title" : "Mitochondrial dysfunction is involved in apoptosis induced by serumwithdrawal and fatty acids in the beta-cell line INS-1",
      "author" : [ "I. Maestre", "J. Jordán", "S. Calvo", "J.A. Reig", "V. Ceña", "B. Soria", "M. Prentki", "E. Roche" ],
      "venue" : "Endocrinology",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2003
    }, {
      "title" : "Mechanisms of beta-cell death in type 2 diabetes",
      "author" : [ "M.Y. Donath", "J.A. Ehses", "K. Maedler", "D.M. Schumann", "H. Ellingsgaard", "E. Eppler", "M. Reinecke" ],
      "venue" : "Diabetes",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2005
    }, {
      "title" : "2005)Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes",
      "author" : [ "M. Cnop", "N. Welsh", "J.C. Jonas", "A. Jörns", "S. Lenzen", "D.L. andEizirik" ],
      "venue" : null,
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2005
    }, {
      "title" : "Type 2 diabetes-a matter of beta-cell life and death",
      "author" : [ "C.J. Rhodes" ],
      "venue" : "Science",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2005
    }, {
      "title" : "Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes",
      "author" : [ "M. Shimabukuro", "Y.T. Zhou", "M. Levi", "R.H. andUnger" ],
      "venue" : "Proc. Natl. Acad. Sci. USA",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 1998
    }, {
      "title" : "Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated",
      "author" : [ "R. Lupi", "F. Dotta", "L. Marselli", "S. DelGuerra", "M. Masini", "C. Santangelo", "G. Patané", "U. Boggi", "S. Piro", "M. Anello", "E. Bergamini", "F. Mosca", "U. Di Mario", "S. Del Prato", "P. Marchetti" ],
      "venue" : "Diabetes",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 2002
    }, {
      "title" : "Initiation and execution of lipotoxic ER stress in pancreatic beta-cells",
      "author" : [ "D.A. Cunha", "P. Hekerman", "L. Ladrière", "A. Bazarra-Castro", "F. Ortis", "M.C. Wakeham", "F. Moore", "J. Rasschaert", "A.K. Cardozo", "E. Bellomo", "L. Overbergh", "C. Mathieu", "R. Lupi", "T. Hai", "A. Herchuelz", "P. Marchetti", "G.A. Rutter", "D.L. Eizirik", "M. Cnop" ],
      "venue" : "J. Cell Sci",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 2008
    }, {
      "title" : "Lipotoxicity is glucosedependent in INS-1E cells but not in human islets and MIN6 cells",
      "author" : [ "E. Sargsyan", "P. Bergsten" ],
      "venue" : "Lipids Health Dis",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 2011
    }, {
      "title" : "Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes",
      "author" : [ "M.Y. Donath", "D.J. Gross", "E. Cerasi", "N. Kaiser" ],
      "venue" : "Diabetes",
      "citeRegEx" : "44",
      "shortCiteRegEx" : "44",
      "year" : 1999
    }, {
      "title" : "Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets",
      "author" : [ "K. Maedler", "G.A. Spinas", "R. Lehmann", "P. Sergeev", "M. Weber", "A. Fontana", "N. Kaiser", "M.Y. Donath" ],
      "venue" : "Diabetes",
      "citeRegEx" : "45",
      "shortCiteRegEx" : "45",
      "year" : 2001
    }, {
      "title" : "High glucose causes apoptosis in culturedhumanpancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death",
      "author" : [ "M. Federici", "M. Hribal", "L. Perego", "M. Ranalli", "Z. Caradonna", "C. Perego", "L. Usellini", "R. Nano", "P. Bonini", "F. Bertuzzi", "L.N. Marlier", "A.M. Davalli", "O. Carandente", "A.E. Pontiroli", "G. Melino", "P. Marchetti", "R. Lauro", "G. Sesti", "F. Folli" ],
      "venue" : "program. Diabetes",
      "citeRegEx" : "46",
      "shortCiteRegEx" : "46",
      "year" : 2001
    }, {
      "title" : "Glucose and leptin  induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases",
      "author" : [ "K. Maedler", "F.T. Schulthess", "C. Bielman", "T. Berney", "C. Bonny", "M. Prentki", "M.Y. Donath", "R. Roduit" ],
      "venue" : "FASEB J",
      "citeRegEx" : "47",
      "shortCiteRegEx" : "47",
      "year" : 2008
    }, {
      "title" : "Overexpression of IRS2 in isolated pancreatic islets causes proliferation and protects human beta-cells from hyperglycemia-induced apoptosis",
      "author" : [ "S. Mohanty", "G.A. Spinas", "K. Maedler", "R.A. Zuellig", "R. Lehmann", "M.Y. Donath", "T. Trüb", "M. Niessen" ],
      "venue" : "Exp. Cell Res",
      "citeRegEx" : "48",
      "shortCiteRegEx" : "48",
      "year" : 2005
    }, {
      "title" : "Eicosanoids as pluripotential modulators of pancreatic islet function",
      "author" : [ "R.P. Robertson" ],
      "venue" : "Diabetes",
      "citeRegEx" : "49",
      "shortCiteRegEx" : "49",
      "year" : 1988
    }, {
      "title" : "Interleukin 1-induced prostaglandin E2 accumulation by isolated pancreatic",
      "author" : [ "J.H. Hughes", "R.A. Easom", "B.A. Wolf", "J. Turk", "M.L. andMcDaniel" ],
      "venue" : "islets. Diabetes",
      "citeRegEx" : "50",
      "shortCiteRegEx" : "50",
      "year" : 1989
    }, {
      "title" : "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function",
      "author" : [ "P.O. Tran", "C.E. Gleason", "R.P. Robertson" ],
      "venue" : "Diabetes",
      "citeRegEx" : "51",
      "shortCiteRegEx" : "51",
      "year" : 2002
    }, {
      "title" : "Enriching islet phospholipids with eicosapentaenoic acid reduces prostaglandin E2 signaling and enhances diabetic b-cell function",
      "author" : [ "J.C. Neuman", "M.D. Schaid", "A.L. Brill", "R.J. Fenske", "C.R. Kibbe", "D.A. Fontaine", "S.M. Sdao", "H.K. Brar", "K.M. Connors", "H.N. Wienkes", "K.W. Eliceiri", "M.J. Merrins", "D.B. Davis", "M.E. Kimple" ],
      "venue" : "Diabetes",
      "citeRegEx" : "52",
      "shortCiteRegEx" : "52",
      "year" : 2017
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Because most individuals with T2D, whether obese or lean, show a decrease in b-cell mass (1, 2), there is a growing interest in understanding the mechanisms that control b-cell survival and death.",
      "startOffset" : 89,
      "endOffset" : 95
    }, {
      "referenceID" : 1,
      "context" : "Because most individuals with T2D, whether obese or lean, show a decrease in b-cell mass (1, 2), there is a growing interest in understanding the mechanisms that control b-cell survival and death.",
      "startOffset" : 89,
      "endOffset" : 95
    }, {
      "referenceID" : 5,
      "context" : "Lipid infusion in individuals who are genetically predisposed to T2D induces hepatic insulin resistance and impairs b-cell function (6).",
      "startOffset" : 132,
      "endOffset" : 135
    }, {
      "referenceID" : 5,
      "context" : "Individuals with high fasting levels of plasma FFAs have an elevated risk of developing T2D (6, 7).",
      "startOffset" : 92,
      "endOffset" : 98
    }, {
      "referenceID" : 6,
      "context" : "Individuals with high fasting levels of plasma FFAs have an elevated risk of developing T2D (6, 7).",
      "startOffset" : 92,
      "endOffset" : 98
    }, {
      "referenceID" : 10,
      "context" : "The activation of the cyclooxygenase-2 (COX-2)–prostanoid pathway has been implicated in the pathogenesis of inflammatory diseases (11).",
      "startOffset" : 131,
      "endOffset" : 135
    }, {
      "referenceID" : 11,
      "context" : "Previous reports have indicated that COX-2 expression was induced in human islets exposed to high glucose andwas elevated in islets of db/dbmice, a mousemodel of T2D (12, 13).",
      "startOffset" : 166,
      "endOffset" : 174
    }, {
      "referenceID" : 12,
      "context" : "Previous reports have indicated that COX-2 expression was induced in human islets exposed to high glucose andwas elevated in islets of db/dbmice, a mousemodel of T2D (12, 13).",
      "startOffset" : 166,
      "endOffset" : 174
    }, {
      "referenceID" : 13,
      "context" : "Important for this study, transgenic mice overexpressing COX-2 and themicrosomal PGE synthase 1 (mPGES-1) genes in b-cells showed a significant reduction in b-cell mass and severe hyperglycemia (14).",
      "startOffset" : 194,
      "endOffset" : 198
    }, {
      "referenceID" : 14,
      "context" : "Selective COX-2 inhibitors were previously tested and showed improved glucose-stimulated insulin secretion (GSIS) in INS-1E cells (15, 16) and inmouse islets (17), as well as a slight increase in insulin secretion in vivo in mice following a glucose load (17).",
      "startOffset" : 130,
      "endOffset" : 138
    }, {
      "referenceID" : 15,
      "context" : "Selective COX-2 inhibitors were previously tested and showed improved glucose-stimulated insulin secretion (GSIS) in INS-1E cells (15, 16) and inmouse islets (17), as well as a slight increase in insulin secretion in vivo in mice following a glucose load (17).",
      "startOffset" : 130,
      "endOffset" : 138
    }, {
      "referenceID" : 16,
      "context" : "Selective COX-2 inhibitors were previously tested and showed improved glucose-stimulated insulin secretion (GSIS) in INS-1E cells (15, 16) and inmouse islets (17), as well as a slight increase in insulin secretion in vivo in mice following a glucose load (17).",
      "startOffset" : 158,
      "endOffset" : 162
    }, {
      "referenceID" : 16,
      "context" : "Selective COX-2 inhibitors were previously tested and showed improved glucose-stimulated insulin secretion (GSIS) in INS-1E cells (15, 16) and inmouse islets (17), as well as a slight increase in insulin secretion in vivo in mice following a glucose load (17).",
      "startOffset" : 255,
      "endOffset" : 259
    }, {
      "referenceID" : 20,
      "context" : "others reported a lack of inhibitory effect on insulin secretion in rat (21, 22) and human islets (21, 23).",
      "startOffset" : 72,
      "endOffset" : 80
    }, {
      "referenceID" : 21,
      "context" : "others reported a lack of inhibitory effect on insulin secretion in rat (21, 22) and human islets (21, 23).",
      "startOffset" : 72,
      "endOffset" : 80
    }, {
      "referenceID" : 20,
      "context" : "others reported a lack of inhibitory effect on insulin secretion in rat (21, 22) and human islets (21, 23).",
      "startOffset" : 98,
      "endOffset" : 106
    }, {
      "referenceID" : 22,
      "context" : "others reported a lack of inhibitory effect on insulin secretion in rat (21, 22) and human islets (21, 23).",
      "startOffset" : 98,
      "endOffset" : 106
    }, {
      "referenceID" : 23,
      "context" : "Moreover, an antiapoptotic effect of PGE2 and its precursor arachidonic acid in MIN6 and BRIN-BD11 cells was suggested (24, 25).",
      "startOffset" : 119,
      "endOffset" : 127
    }, {
      "referenceID" : 24,
      "context" : "Moreover, an antiapoptotic effect of PGE2 and its precursor arachidonic acid in MIN6 and BRIN-BD11 cells was suggested (24, 25).",
      "startOffset" : 119,
      "endOffset" : 127
    }, {
      "referenceID" : 25,
      "context" : "The EP subtypes exhibit differences in signal transduction, tissue localization, and regulation of expression (26).",
      "startOffset" : 110,
      "endOffset" : 114
    }, {
      "referenceID" : 29,
      "context" : "The involvement of PGE2 and EP3 in b-cell survival and proliferation in mouse and human islets in the presence of cytokines (30) has been reported.",
      "startOffset" : 124,
      "endOffset" : 128
    }, {
      "referenceID" : 28,
      "context" : "Elevatedexpressionof theEP3receptor in islets isolatedfrom individuals with T2D has previously been reported (29, 30); in the present study we support these findings and bring evidenceof elevatedexpressionof theEP3 receptor inb-cells exposed to palmitate or PGE2.",
      "startOffset" : 109,
      "endOffset" : 117
    }, {
      "referenceID" : 29,
      "context" : "Elevatedexpressionof theEP3receptor in islets isolatedfrom individuals with T2D has previously been reported (29, 30); in the present study we support these findings and bring evidenceof elevatedexpressionof theEP3 receptor inb-cells exposed to palmitate or PGE2.",
      "startOffset" : 109,
      "endOffset" : 117
    }, {
      "referenceID" : 30,
      "context" : "Berta Brodsky (31), HebrewUniversity, Israel.",
      "startOffset" : 14,
      "endOffset" : 18
    }, {
      "referenceID" : 31,
      "context" : "The pancreatic b-cell line MIN6 (32) was cultured in DMEM (Biologic Industries, Beit Haemek, Israel) supplemented with 11 mM glucose, 2 mM glutamine, 15% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, and 61 mM b-mercaptoethanol.",
      "startOffset" : 32,
      "endOffset" : 36
    }, {
      "referenceID" : 32,
      "context" : "Acute insulin release in response to glucose stimulation and insulin content was measured in human islets as previously described (33).",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 11,
      "context" : "islets cultured in high glucose (12, 13) and db/db mouse islets (12, 13).",
      "startOffset" : 32,
      "endOffset" : 40
    }, {
      "referenceID" : 12,
      "context" : "islets cultured in high glucose (12, 13) and db/db mouse islets (12, 13).",
      "startOffset" : 32,
      "endOffset" : 40
    }, {
      "referenceID" : 11,
      "context" : "islets cultured in high glucose (12, 13) and db/db mouse islets (12, 13).",
      "startOffset" : 64,
      "endOffset" : 72
    }, {
      "referenceID" : 12,
      "context" : "islets cultured in high glucose (12, 13) and db/db mouse islets (12, 13).",
      "startOffset" : 64,
      "endOffset" : 72
    }, {
      "referenceID" : 2,
      "context" : "Increased b-cell death following exposure to palmitate is well documented (3, 4), as supported by the results presented in Fig.",
      "startOffset" : 74,
      "endOffset" : 80
    }, {
      "referenceID" : 3,
      "context" : "Increased b-cell death following exposure to palmitate is well documented (3, 4), as supported by the results presented in Fig.",
      "startOffset" : 74,
      "endOffset" : 80
    }, {
      "referenceID" : 32,
      "context" : "Thepresent study is a follow-up study to aprevious report in which human islets chronically exposed to high glucose showed a reduced expression of the insulin and pancreatic duodenal homeobox 1 genes (33).",
      "startOffset" : 200,
      "endOffset" : 204
    }, {
      "referenceID" : 33,
      "context" : "Higher fasting FFA levels were prospectively found to be associated with a greater risk of subsequent impaired glucose tolerance and T2D (34).",
      "startOffset" : 137,
      "endOffset" : 141
    }, {
      "referenceID" : 34,
      "context" : "Fatty acids can favor the development of the disease by reducing insulin secretion and inducing apoptosis of pancreatic b cells (35, 36).",
      "startOffset" : 128,
      "endOffset" : 136
    }, {
      "referenceID" : 35,
      "context" : "Fatty acids can favor the development of the disease by reducing insulin secretion and inducing apoptosis of pancreatic b cells (35, 36).",
      "startOffset" : 128,
      "endOffset" : 136
    }, {
      "referenceID" : 4,
      "context" : "This vicious cycle of lipotoxicity results in b-cell failure and apoptosis (5).",
      "startOffset" : 75,
      "endOffset" : 78
    }, {
      "referenceID" : 13,
      "context" : "These observations are in linewith the results of a study that examined the in vivo effect of b-cell–specific expression of COX-2 in transgenic mice (14).",
      "startOffset" : 149,
      "endOffset" : 153
    }, {
      "referenceID" : 42,
      "context" : "This is in agreement with a report showing that high glucose increased apoptosis only in INS-1E but not in MIN6 or human islets, which were suggested to efficiently oxidize fatty acids at high glucose and therefore prevent the synergism suggested in glucolipotoxicity-induced apoptosis (43).",
      "startOffset" : 286,
      "endOffset" : 290
    }, {
      "referenceID" : 20,
      "context" : "The discrepancy could be due to the different experimental conditions used as well as to the originof theb cells tested suchasHITcells, or rat orhuman islets (21, 22, 49, 50).",
      "startOffset" : 158,
      "endOffset" : 174
    }, {
      "referenceID" : 21,
      "context" : "The discrepancy could be due to the different experimental conditions used as well as to the originof theb cells tested suchasHITcells, or rat orhuman islets (21, 22, 49, 50).",
      "startOffset" : 158,
      "endOffset" : 174
    }, {
      "referenceID" : 48,
      "context" : "The discrepancy could be due to the different experimental conditions used as well as to the originof theb cells tested suchasHITcells, or rat orhuman islets (21, 22, 49, 50).",
      "startOffset" : 158,
      "endOffset" : 174
    }, {
      "referenceID" : 49,
      "context" : "The discrepancy could be due to the different experimental conditions used as well as to the originof theb cells tested suchasHITcells, or rat orhuman islets (21, 22, 49, 50).",
      "startOffset" : 158,
      "endOffset" : 174
    }, {
      "referenceID" : 25,
      "context" : "These receptors are distinct based on: 1) their binding affinity to the ligand, 2) the relative activity of different specific pharmacologic agonists or antagonists, and 3) the differences in signal transduction, tissue localization, and regulation of expression they exhibit under physiologic and pathologic conditions (26).",
      "startOffset" : 320,
      "endOffset" : 324
    }, {
      "referenceID" : 50,
      "context" : "In accordance with the findings in rats (51) and in humans (29), the most prevalent receptor in human islets is EP3.",
      "startOffset" : 40,
      "endOffset" : 44
    }, {
      "referenceID" : 28,
      "context" : "In accordance with the findings in rats (51) and in humans (29), the most prevalent receptor in human islets is EP3.",
      "startOffset" : 59,
      "endOffset" : 63
    }, {
      "referenceID" : 28,
      "context" : "Consistent with previous observation, a selective elevated expression in T2D islets was observed only in EP3 and not in the additional PGE2 receptors EP1, EP2, and EP4 (29, 30).",
      "startOffset" : 168,
      "endOffset" : 176
    }, {
      "referenceID" : 29,
      "context" : "Consistent with previous observation, a selective elevated expression in T2D islets was observed only in EP3 and not in the additional PGE2 receptors EP1, EP2, and EP4 (29, 30).",
      "startOffset" : 168,
      "endOffset" : 176
    }, {
      "referenceID" : 26,
      "context" : "(27) suggested that the deleterious effects of IL-1b on b-cell functions involved the activation of NF-kB, which stimulates COX-2 expression.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 28,
      "context" : "EP3was also reported to be elevated in islets from diabetic BTBR mice and human T2D, and it was found that the EP3 antagonist improves GSIS (29).",
      "startOffset" : 140,
      "endOffset" : 144
    }, {
      "referenceID" : 29,
      "context" : "PGE2 signaling via EP3 results in impaired b-cell proliferation in oldmice (30).",
      "startOffset" : 75,
      "endOffset" : 79
    }, {
      "referenceID" : 51,
      "context" : "(52) presented a different approach of showing the involvement of EP3 in b-cell function.",
      "startOffset" : 0,
      "endOffset" : 4
    } ],
    "year" : 2019,
    "abstractText" : "Elevated levels of lipids, in particular saturated fatty acids, are known to be associated with type 2 diabetes (T2D) and to have a negative effect onb-cell function and survival.We bring newevidence indicating that palmitateup-regulatescyclooxygenase-2 (COX-2)expression levels inhuman isletsand inMIN6b cells, and that it is elevated in islets isolated fromT2Ddonors. Both small interfering specific cyclooxygenase-2 small interferingRNA (siRNA) or the COX-2 inhibitor celecoxib significantly inhibited apoptosis induced by palmitate. Prostaglandin E2 (PGE2), thepredominantproduct ofCOX-2enzymatic activity, activatesmembrane receptors,whicharemembersof the GPCR-family (EP1–EP4). In the present study, elevated expression of the PGE2 receptor subtype 3 (EP3) receptor was observedinb cellsexposedtopalmitateand in islets fromindividualswithT2D.Down-regulationof thepathwayusing EP3 siRNA or the specific L-798,106 antagonist markedly decreased the levels of palmitate-induced apoptosis. Altogether, our data put forward the COX-2-PGE2-EP3 pathway as one of the mediators of palmitate-induced apoptosis in b-cells.—Amior,L.,Srivastava,R.,Nano,R.,Bertuzzi,F.,Melloul,D.TheroleofCox-2andprostaglandinE2receptorEP3 in pancreatic b-cell death. FASEB J. 33, 000–000 (2019). www.fasebj.org",
    "creator" : "Arbortext Advanced Print Publisher 9.1.510/W Unicode"
  }
}